Literature DB >> 3468997

The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. IV. Analysis of survival and prognostic features.

J V Melo, D Catovsky, W M Gregory, D A Galton.   

Abstract

The prognostic value of biological, clinical and laboratory features was analysed in a series of 265 patients with chronic lymphocytic leukaemia (CLL) and prolymphocytic leukaemia (PLL). On univariate analysis seven features were shown to influence significantly the survival of the whole group of patients: absolute prolymphocyte count (ABS PROL), percentage of prolymphocytes (%PROL), WBC, spleen size, age, intensity of surface-membrane immunoglobulin (SmIg) and mouse (M) rosettes. Multivariate regression analysis of these features showed that only ABS PROL and spleen size had independent prognostic significance. The survival in PLL (38 cases) was significantly shorter than in CLL (227 cases) (median survival = 3 and 8 years, respectively). Patients with CLL with an increased %PROL (11-55%), defined as CLL/PL, could be divided into two groups: those with ABS PROL less than or equal to 15 X 10(9)/l (26 cases) fell within the 'standard-prognostic risk' for typical CLL (i.e. less than or equal to 10% PROL), whereas the survival outlook for the cases with ABS PROL greater than 15 X 10(9)/l (40 cases) was as bad as for PLL. A scoring system was generated with the four features that showed high prognostic significance: ABS PROL, spleen size, SmIg and M-rosettes. The score proved to be superior to any single feature as a predictor of survival, being especially useful in the analysis of the CLL/PL group: cases with high scores (greater than 2) had a median survival of 2.5 years, while the median has not been reached for those with low scores (less than or equal to 2). We suggest that this scoring system may help to identify the cases of CLL/PL that behave as PLL, and as such may benefit from different treatment.

Entities:  

Mesh:

Year:  1987        PMID: 3468997     DOI: 10.1111/j.1365-2141.1987.tb06130.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  J Clin Pathol       Date:  1989-06       Impact factor: 3.411

Review 2.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

3.  Nucleolar organiser regions in lymphocytes of patients with chronic lymphocytic leukaemia.

Authors:  P Kaur; D W Milligan; J Crocker
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

4.  Morphology and immunology of circulating cells in leukaemic phase of follicular lymphoma.

Authors:  J V Melo; D S Robinson; M P De Oliveira; I W Thompson; I A Lampert; J P Ng; D A Galton; D Catovsky
Journal:  J Clin Pathol       Date:  1988-09       Impact factor: 3.411

5.  Expression of Ki-67 nuclear antigen in B and T cell lymphoproliferative disorders.

Authors:  N de Melo; E Matutes; I Cordone; R Morilla; D Catovksy
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

Review 6.  New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia.

Authors:  C M Wendtner; B Schmitt; M Bergmann; T Röhnisch; R Buhmann; M Hallek
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.319

7.  The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial.

Authors:  David Oscier; Monica Else; Estella Matutes; Ricardo Morilla; Jonathan C Strefford; Daniel Catovsky
Journal:  Br J Haematol       Date:  2016-05-06       Impact factor: 6.998

8.  Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.

Authors:  Nina Kreuzberger; Johanna Aag Damen; Marialena Trivella; Lise J Estcourt; Angela Aldin; Lisa Umlauff; Maria Dla Vazquez-Montes; Robert Wolff; Karel Gm Moons; Ina Monsef; Farid Foroutan; Karl-Anton Kreuzer; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-07-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.